FDA Approves First IND of its Kind for Allogenic Exosomal Treatment of Female Reproductive Disorder
yahoo.com
finance
2022-10-18 12:46:00

LIBERTY, Mo., Oct. 18, 2022 /PRNewswire/ -- Vitti Labs, an AATB Accredited Tissue Bank focused on life science research, development, and manufacturing, announced today that the U.S. Food and Drug Administration (FDA) has approved their Investigational New Drug Application (IND) of EV-Pure, an allogenic exosomal product, for women with Primary Ovarian Insufficiency or POI. The approved human clinical trial is based on non-clinical studies in cell culture and animal models utilizing EV-Pure, which indicated a strong promise for the reversal of POI.
